Biomea Fusion BMEA
NASDAQ BMEA
$0.58 -0.11 (-15.94%)
At close: Oct 22, 2026 · 4:00 PM EDT

Biomea Fusion (BMEA) Gains from Sales and Divestitures (2026)

Updated

Biomea Fusion (BMEA) recorded Gains from Sales and Divestitures of $510,000 in Q1 2026.

Analysis

Biomea Fusion (BMEA) Gains from Sales and Divestitures (2026) Analysis & Trends

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,230.11 Bn 1,198.70 Bn 19.71 Bn
2 Johnson & Johnson 644.39 Bn 564.25 Bn 17.30 Bn
3 AbbVie 503.52 Bn 476.68 Bn 12.70 Bn
4 Merck 363.29 Bn 317.72 Bn 12.21 Bn
5 Novartis Ag 298.23 Bn 262.62 Bn 11.24 Bn
6 Astrazeneca 267.53 Bn 241.29 Bn 12.86 Bn
7 Amgen 241.80 Bn 197.20 Bn 7.24 Bn
8 Gilead Sciences 195.07 Bn 169.19 Bn 6.22 Bn
9 Pfizer 173.33 Bn 120.28 Bn 10.94 Bn
10 Biomea Fusion 42.04 Mn -140.30 Mn -
Historic Data

Historic Data

Download Data
DateValue
Mar 31, 2026 510,000.00
API Access

Biomea Fusion Gains from Sales and Divestitures API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=gains-from-sales-and-divestitures&ticker=BMEA&period=max&api_key=YOUR_API_KEY